Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993844 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer, sponsored by Ensem Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 233
- Enrollment target
- 10
- Study locations
NCT06993844: Recruiting Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer, sponsored by Ensem Therapeutics.
NCT06993844 is a Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer that is actively recruiting participants, run by Ensem Therapeutics. The registered enrollment target is 233 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (18% higher). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06993844, a Phase 1 study of Advanced Solid Tumors and Advanced Breast Cancer, is actively recruiting participants, sponsored by Ensem Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 233 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
Primary Outcome
Proportion of participants who experience at least 1 Dose Limiting Toxicity (DLT)
Conditions Studied
Interventions
- DRUG ETX-636 dose escalation
- DRUG ETX-636 dose escalation in combination with fulvestrant
- DRUG ETX-636 dose expansion in combination with fulvestrant
Study Locations (10)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- START - San Antonio
Connecticut
- Yale University, Yale Cancer Center - New Haven
North Carolina
- Carolina BioOncology Institute - Huntersville
Virginia
- NEXT - Fairfax
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 1 |
What NCT06993844 shows while recruiting
NCT06993844 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (18% higher).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which ETX-636 dose escalation is the first listed.
NCT06993844 lists 10 locations in 7 states (California, Massachusetts, Texas).
Frequently Asked Questions
What is clinical trial NCT06993844 about?
NCT06993844 is a clinical study titled "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors". Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
What is the current status of trial NCT06993844?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 233 participants. The study started on 2025-06-10. Estimated completion is 2027-12-30.
What conditions does trial NCT06993844 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Advanced Breast Cancer.
What interventions are being tested in trial NCT06993844?
The interventions under investigation include: ETX-636 dose escalation (DRUG), ETX-636 dose escalation in combination with fulvestrant (DRUG), ETX-636 dose expansion in combination with fulvestrant (DRUG).
Who is sponsoring clinical trial NCT06993844?
This trial is sponsored by Ensem Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993844 being conducted?
This trial has 10 study locations across California, Connecticut, Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06993844's enrollment target sits among peer trials
233 39th of 144 higher than 106 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI